UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

Generic antiepileptic drugs and associated medical resource utilization in the United States

Neurology, 2010-05, Vol.74 (20), p.1566

2010

Volltextzugriff (PDF)

Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma

Leukemia, 2016-04, Vol.30 (4), p.995-998

2016

Volltextzugriff (PDF)

Health characteristics of patients with asthma, COPD and asthma-COPD overlap in the NHANES database

International journal of chronic obstructive pulmonary disease, 2018-01, Vol.13, p.2859-2868

2018

Volltextzugriff (PDF)

Burden of disease associated with a COPD eosinophilic phenotype

International journal of chronic obstructive pulmonary disease, 2018-01, Vol.13, p.2425-2433

2018

Volltextzugriff (PDF)

Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization

Neurology, 2012-10, Vol.79 (18), p.1908

2012

Volltextzugriff (PDF)

MA12.05 Economic Impact of Delaying Care with Single-Gene Testing Versus Next-Generation Sequencing in Non-small Cell Lung Cancer

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S86-S87

2022

Volltextzugriff (PDF)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab

Biologics, 2021-01, Vol.15, p.1-15

2021

Volltextzugriff (PDF)

Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia

Patient preference and adherence, 2023-09, Vol.17, p.2073-2084

2023

Volltextzugriff (PDF)

Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Naïve People Living with HIV-1

ClinicoEconomics and outcomes research, 2023-01, Vol.15, p.579-591

2023

Volltextzugriff (PDF)

Treatment Patterns and Predictors of Adherence in HIV Patients Receiving Single- or Multiple-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide

Patient preference and adherence, 2020-01, Vol.14, p.2315-2326

2020

Volltextzugriff (PDF)

C31 CLINICAL ASTHMA I: Economic And Clinical Burden Of Acute And Chronic Systemic Corticosteroid-Related Complications In Asthma Patients

American journal of respiratory and critical care medicine, 2015-01, Vol.191, p.1

2015

Volltextzugriff (PDF)

Cost Offsets in the Treatment Journeys of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood, 2017, Vol.130, p.5599-5599

2017

Volltextzugriff (PDF)

Risk of Hepatotoxicity-Related Hospitalizations among Patients Treated with Opioid/Acetaminophen Combination Prescription Pain Medications

Pain medicine (Malden, Mass.), 2010-11, Vol.11 (11), p.1718-1725

2010

Volltextzugriff (PDF)

PCN25 DRUG UTILIZATION AND COSTS FOR ERYTHROPOIESIS STIMULATING AGENTS (ESA) IN PATIENTS WITH BREAST, LUNG, OR GASTROINTESTINAL CANCER RECEIVING CHEMOTHERAPY

Value in health, 2009, Vol.12 (3), p.A40-A40

2009

Volltextzugriff (PDF)

PCN98 IMPACT OF RECENT ERYTHROPOIESIS-STIMULATING AGENT (ESA) POLICY CHANGES ON DOSING PATTERNS IN CANCER CHEMOTHERAPY PATIENTS

Value in health, 2009, Vol.12 (3), p.A55-A55

2009

Volltextzugriff (PDF)

DU6 ASSESSMENT OF DRUG UTILIZATION PATTERNS AND COSTS FOR ERYTHROPOIETIC STIMULATING AGENTS IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE

Value in health, 2008, Vol.11 (3), p.A23-A23

2008

Volltextzugriff (PDF)

PCN89 DRUG UTILIZATION PATTERNS AND COSTS FOR ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN A MANAGED CARE CANCER POPULATION RECEIVING CHEMOTHERAPY

Value in health, 2008, Vol.11 (3), p.A81-A81

2008

Volltextzugriff (PDF)

PCN49 COSTS TO MEDICARE OF TREATING CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH ALEMTUZUMAB

Value in health, 2010, Vol.13 (3), p.A32-A32

2010

Volltextzugriff (PDF)

PUK8 ERYTHROPOIESIS-STIMULATING AGENTS UTILIZATION AND COSTS IN PATIENTS WITH CHRONIC KIDNEY DISEASE NOT ON DIALYSIS FROM TWO LARGE CLAIMS DATABASES

Value in health, 2010, Vol.13 (3), p.A77-A77

2010

Volltextzugriff (PDF)

PUK27 ERYTHROPOIESIS-STIMULATING AGENT DOSING AND HEMOGLOBIN TRENDS OVER TIME IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS

Value in health, 2010, Vol.13 (3), p.A81-A81

2010

Volltextzugriff (PDF)

PUK28 ASSESSMENT OF RECENT ERYTHROPOIESIS-STIMULATING AGENT GUIDELINES CHANGES ON DOSING PATTERNS IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS

Value in health, 2010, Vol.13 (3), p.A81-A81

2010

Volltextzugriff (PDF)

PCN26 COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS AND COSTS IN CANCER INPATIENTS RECEIVING CHEMOTHERAPY

Value in health, 2009, Vol.12 (3), p.A40-A41

2009

Volltextzugriff (PDF)

CN1 RECENT ERYTHROPOIESIS-STIMULATING AGENT (ESA) UTILIZATION TREND IN CANCER CHEMOTHERAPY PATIENTS IN A MANAGED CARE AND A HOSPITAL OUTPATIENT SETTING

Value in health, 2009, Vol.12 (3), p.A2-A2

2009

Volltextzugriff (PDF)

DU3 PATTERN OF UTILIZATION OF PEGFILGRASTIM IN PATIENTS WITH CHEMOTHERAPY-INDUCED NEUTROPENIA: A RETROSPECTIVE ANALYSIS OF ADMINISTRATIVE CLAIMS DATA

Value in health, 2009, Vol.12 (3), p.A3-A3

2009

Volltextzugriff (PDF)

PND8 THE IMPACT OF GENERIC SUBSTITUTION OF TOPIRAMATE ON HEALTH CARE COSTS: CONVERSION OF THE CANADIAN EXPERIENCE INTO THE SETTINGS OF G4 EUROPEAN COUNTRIES

Value in health, 2009, Vol.12 (3), p.A191-A191

2009

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(26)
Tagungsberichte
(1)

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

8 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Generic antiepileptic drugs and associated medical resource utilization in the United States

Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma

Health characteristics of patients with asthma, COPD and asthma-COPD overlap in the NHANES database

Burden of disease associated with a COPD eosinophilic phenotype

Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization

MA12.05 Economic Impact of Delaying Care with Single-Gene Testing Versus Next-Generation Sequencing in Non-small Cell Lung Cancer

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab

Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia

Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Naïve People Living with HIV-1

Treatment Patterns and Predictors of Adherence in HIV Patients Receiving Single- or Multiple-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide

C31 CLINICAL ASTHMA I: Economic And Clinical Burden Of Acute And Chronic Systemic Corticosteroid-Related Complications In Asthma Patients

Cost Offsets in the Treatment Journeys of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Risk of Hepatotoxicity-Related Hospitalizations among Patients Treated with Opioid/Acetaminophen Combination Prescription Pain Medications

PCN25 DRUG UTILIZATION AND COSTS FOR ERYTHROPOIESIS STIMULATING AGENTS (ESA) IN PATIENTS WITH BREAST, LUNG, OR GASTROINTESTINAL CANCER RECEIVING CHEMOTHERAPY

PCN98 IMPACT OF RECENT ERYTHROPOIESIS-STIMULATING AGENT (ESA) POLICY CHANGES ON DOSING PATTERNS IN CANCER CHEMOTHERAPY PATIENTS

DU6 ASSESSMENT OF DRUG UTILIZATION PATTERNS AND COSTS FOR ERYTHROPOIETIC STIMULATING AGENTS IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE

PCN89 DRUG UTILIZATION PATTERNS AND COSTS FOR ERYTHROPOIESIS-STIMULATING AGENTS (ESAS) IN A MANAGED CARE CANCER POPULATION RECEIVING CHEMOTHERAPY

PCN49 COSTS TO MEDICARE OF TREATING CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH ALEMTUZUMAB

PUK8 ERYTHROPOIESIS-STIMULATING AGENTS UTILIZATION AND COSTS IN PATIENTS WITH CHRONIC KIDNEY DISEASE NOT ON DIALYSIS FROM TWO LARGE CLAIMS DATABASES

PUK27 ERYTHROPOIESIS-STIMULATING AGENT DOSING AND HEMOGLOBIN TRENDS OVER TIME IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS

PUK28 ASSESSMENT OF RECENT ERYTHROPOIESIS-STIMULATING AGENT GUIDELINES CHANGES ON DOSING PATTERNS IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS

PCN26 COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS AND COSTS IN CANCER INPATIENTS RECEIVING CHEMOTHERAPY

CN1 RECENT ERYTHROPOIESIS-STIMULATING AGENT (ESA) UTILIZATION TREND IN CANCER CHEMOTHERAPY PATIENTS IN A MANAGED CARE AND A HOSPITAL OUTPATIENT SETTING

DU3 PATTERN OF UTILIZATION OF PEGFILGRASTIM IN PATIENTS WITH CHEMOTHERAPY-INDUCED NEUTROPENIA: A RETROSPECTIVE ANALYSIS OF ADMINISTRATIVE CLAIMS DATA

PND8 THE IMPACT OF GENERIC SUBSTITUTION OF TOPIRAMATE ON HEALTH CARE COSTS: CONVERSION OF THE CANADIAN EXPERIENCE INTO THE SETTINGS OF G4 EUROPEAN COUNTRIES

Suchergebnisse filtern